000 03683nam a22004695i 4500
001 978-1-4614-8869-9
003 DE-He213
005 20140220082832.0
007 cr nn 008mamaa
008 130913s2013 xxu| s |||| 0|eng d
020 _a9781461488699
_9978-1-4614-8869-9
024 7 _a10.1007/978-1-4614-8869-9
_2doi
050 4 _aQR180-189.5
072 7 _aMJCM
_2bicssc
072 7 _aMED044000
_2bisacsh
082 0 4 _a616.079
_223
100 1 _aKumar, Awanish.
_eauthor.
245 1 0 _aLeishmania and Leishmaniasis
_h[electronic resource] /
_cby Awanish Kumar.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Springer,
_c2013.
300 _aXI, 83 p. 14 illus., 11 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aSpringerBriefs in Immunology,
_x2194-2773 ;
_v3
505 0 _aHistorical background of Leishmania and leishmaniasis -- Risk factors and definition of the problem -- Types of leishmaniasis -- Global status of visceral leishmaniasis -- Status of visceral leishmaniasis in India -- Morphology and Life cycle of Leishmania donovani -- Vectors and transmission of the disease -- Clinical symptoms of visceral leishmaniasis -- Control strategies of the disease -- Leishmania/HIV co-infections -- Host Immune response to Leishmania infection -- Cross-immunity between different Leishmania species -- Adoptive transfer of immunity -- Cutaneous leishmaniasis -- Mucocutaneous Leishmaniasis -- Visceral Leishmaniasis -- Post Kala-azar dermal Leishmaniasis -- Drugs against leishmaniasis -- Antimonials and Leishmaniasis -- SAG treatment, failure and resistance in Leishmania -- Vaccines against Leishmaniasis -- Strategy in practice for vaccine development against Leishmanisis.
520 _aLeishmania-related illnesses remain among the world’s deadliest neglected tropical diseases, affecting approximately 12 million people in 88 countries. The mortality rate is substantial, contributing to nearly two million disability-adjusted life years. As more is understood about this parasite and its effects, work toward prevention, control, and treatment continues apace. Leishmania and Leishmaniasis will address the parasite and its attendant disease, which manifests in three syndromes: Visceral (VL), Cutaneous (CL) and Mucocutaneous Leishmaniasis (ML). The morphology and life cycles of the various species will be among the topics addressed in Part One. Part Two will focus on immunology, including host-immune response to Leishmania infection, cross-immunity between the different species and adoptive transfer of immunity. Parts Three and Four will address how Leishmania invade and survive, the clinical features of the disease, and its diagnosis.  Drugs, vaccines and treatment will be thoroughly explored, including experimental models of therapeutics. Leishmania and Leishmaniasis will provide a thorough examination of a parasite, the illnesses it causes and the misery it continues to visit upon large segments of the population.
650 0 _aMedicine.
650 0 _aImmunology.
650 0 _aMedical parasitology.
650 1 4 _aBiomedicine.
650 2 4 _aImmunology.
650 2 4 _aParasitology.
650 2 4 _aBiomedicine general.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781461488682
830 0 _aSpringerBriefs in Immunology,
_x2194-2773 ;
_v3
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4614-8869-9
912 _aZDB-2-SBL
999 _c96091
_d96091